Showing 2951-2960 of 5973 results for "".
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- InfoRx App from Vivacare Enables Dermatologists to Deliver Personalized Patient Education Resourceshttps://practicaldermatology.com/news/inforx-app-from-vivacare-enables-dermatologists-to-deliver-personalized-patient-education-resources/2458651/Vivacare announced the release of its InfoRx mobile app that enables dermatologists to deliver personalized patient handouts, videos and other skin care resources into the hands of their patients and family members. The service is available to U.S.-based dermato
- Syneron Candela Introducing New Technologies at the 2016 AAD Annual Meetinghttps://practicaldermatology.com/news/syneron-candela-introducing-new-technologies-at-the-2016-aad-annual-meeting/2458664/Syneron Medical Ltd., is launching three new products during the 2016 American Academy of Dermatology (AAD) meeting in Washington, DC. The launches include the new CO2RE Intima sy
- ALASTIN™ Skincare, Inc. Announces New Scientific Advisory Councilhttps://practicaldermatology.com/news/alastin-skincare-inc-announces-new-scientific-advisory-council/2458667/ALASTIN™ Skincare, Inc., announced its new eight-person Scientific Advisory Council. The Council includes: · Vivian Bucay, M.D., Dermatologist, B
- Dermwire's Inside Scoop on Hottest Expected AAD2016 Launcheshttps://practicaldermatology.com/news/dermwires-inside-scoop-on-hottest-expected-aad2016-launches/2458670/The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest – and hopefully greatest --- innovations or iterations in skin care products and technologies. And the